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ABSTRACT
Animal models and human studies of allogeneic hematopoietic cell transplantation (HCT) demonstrate that
immunologic nonidentity between donor and recipient is responsible for a graft versus leukemia (GVL) effect
that contributes to complete tumor eradication. A variety of immune cells have been implicated in the GVL
effect including NK cells, B cells, and CD4 and CD8 T cells that recognize minor histocompatibility (H) or
leukemia-associated antigens. Here we discuss strategies for employing T cells specific for minor H antigens
to augment the GVL effect.
© 2006 American Society for Blood and Marrow Transplantation
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mNTRODUCTION
The ability of allogeneic hematopoietic cell trans-
lantation (HCT) to cure leukemia represents a con-
picuous example of the capacity of the human im-
une system to destroy tumors. In allogeneic HCT
etween HLA-identical individuals, recognition by
onor T cells of minor histocompatibility (H) anti-
ens, which are peptides derived from endogenous
roteins and presented by major histocompatibility
omplex (MHC) molecules on recipient cells, provides
mechanism by which graft-versus-leukemia (GVL)
ffects can be mediated [1]. Several features of minor
antigens suggest that they are attractive targets for
ntitumor therapy. First, minor H antigens are highly
mmunogenic, and donor T cells cause graft-versus-
ost disease (GVHD) and mediate GVL despite the
dministration of immunosuppressive drugs to block
lloreactivity. Second, most minor H antigen-speciﬁc
-cell clones have high avidity for their cognate an-
igen, thus increasing the likelihood they will recog-
ize tumor cells that may express low levels of MHC.
hird, the T-cell response to minor H antigens involves
oth CD8 and CD4 T-cell subsets and is frequently
irected at multiple determinants. The breadth of rec-
gnition may prevent the outgrowth of tumor cells that
ave lost or reduced levels of antigen expression,
hich has been observed in immunotherapy studies
hat target only a single determinant. However, T-cell p
B&MTecognition of minor H antigens is also responsible for
VHD [2], and a prevailing challenge in allogeneic
CT is to develop approaches that will permit sepa-
ation of the GVL effect from GVHD or abrogate
VHD after tumor eradication is complete.
OLECULAR CHARACTERIZATION OF HUMAN MINOR
ANTIGENS
An improved understanding of the molecular na-
ure and tissue expression of minor H antigens may
acilitate efforts to manipulate GVL activity and sep-
rate it from GVHD. A variety of methods, including
omplementary DNA expression cloning, peptide elu-
ion and mass spectrometry, and genetic linkage anal-
sis, have been used for identifying the polymorphic
enes that encode minor H antigens. Although fewer
han 30 genes that encode minor H antigens have
een discovered, these efforts are providing insight
nto the mechanisms by which genetic polymorphism
esults in immunogenicity, including differential gene
xpression, alterations inMHC binding or T cell–recep-
or contact, alterations in proteosomal processing or
eptide transport, and peptide splicing and reassortment
3-7; unpublished data]. Translating this information
nto strategies that induce a GVL effect based on aug-
enting T-cell responses to minor H antigens has
roven more difﬁcult. Some minor H antigens exhibit
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1referential expression on hematopoietic cells, including
eukemic stem cells [8], and a simple model is that the
issue expression of minor H antigens might provide the
asis for segregating the GVL effect fromGVHD [9]. T
ells that recognize minor H antigens that are selectively
xpressed by recipient hematopoietic cells, including
eukemic cells, could contribute to the elimination of
eukemia without GVHD. Alternatively, T cells that
ecognize antigens that are broadly expressed by both
ematopoietic cells and epithelium might contribute to
oth GVL and GVHD, or GVHD alone (Figure 1).
UMOR-REACTIVE T-CELL RESPONSES AFTER
ONMYELOABLATIVE HCT
Transplantation of donor peripheral blood stem
ells after nonmyeloablative conditioning (NM-HCT)
epresents a circumstance in which donor immune
ells assume paramount importance for tumor eradi-
ation [10], and it provides a distinct opportunity to
haracterize the responses that recognize tumor cells.
M-HCT is particularly effective for indolent hema-
ologic malignancies such as chronic lymphocytic leu-
emia (CLL), in which tumor cells are also readily
ccessible for analysis. In patients receiving NM-HCT
or CLL, we have analyzed the kinetics, phenotype, and
peciﬁcity of alloreactive and tumor-reactive T-cell re-
ponses. A rapid decline in circulating CLL cells is ob-
erved in most patients after transplantation, including
hose with advanced disease and a high tumor burden.
tameH
lleC
cimekueL
lleC
LVG
igure 1. Separation of GVL effects and GVHD according to tissue
hich are selectively expressed on hematopoietic cells, including
pithelial cells. By contrast, T cells that recognize broadly expressed
ffect. APC, antigen-presenting cell.he antitumor effects of transplantation coincide with n
0he development of donor T-cell chimerism and are
ften temporally dissociated from GVHD. In re-
ponding patients, CD4 and CD8 T cells reactive
ith recipient CLL cells are detected in the blood
arly after transplantation and persist for 1 year.
ndividual T-cell clones isolated from responding pa-
ients exhibit cytolytic activity against recipient CLL
ells, and most clones recognize minor H antigens,
hereas a smaller subset seem to recognize tumor-
peciﬁc determinants. These studies demonstrate that
any patients develop potent, early, and sustained
lloreactive and tumor-reactive T-cell responses after
M-HCT that correlate with tumor clearance. Un-
ortunately, not all patients respond to NM-HCT,
nd it is anticipated the isolation and characterization
f T cells in responding patients will enable the de-
elopment of targeted approaches based on adoptive
-cell transfer or vaccination to enhance tumor-reac-
ive T cells after transplantation in nonresponding
atients.
DOPTIVE TRANSFER OF ALLOREACTIVE
-CELL CLONES
Myeloablative regimens are preferred for patients
ith acute leukemia undergoing allogeneic HCT, but
elapse-free survival still relies in part on a GVL effect
11,12]. For patients with advanced acute leukemia at
he time of HCT, relapse remains a major cause of
ailure, and strategies to augment the GVL effect are
muilehtipE
citei
)C
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DHVG
sion of minor H antigens. T cells that recognize minor H antigens,
ic cells, will mediate a GVL effect without inducing damage to
H antigens may induce GVHD alone or concomitant with a GVLopo
PA( 
noD
expres
leukem
minoreeded. On the basis of previous work demonstrating
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Adoptive Transfer of Allogeneic Antigen-Specific T Cells
Bhat the adoptive transfer of donor-derived cytomegalo-
irus-speciﬁc cytotoxic T lymphocyte (CTL) clones can
estore functional cytomegalovirus-speciﬁc immunity
13], we have investigated the adoptive transfer of
-cell clones speciﬁc for minor H antigens to treat
atients with relapse of acute leukemia after allogeneic
CT. At the present time, too few hematopoietic
ineage-restricted minor H antigens have been molec-
larly characterized to prospectively evaluate them as
argets for therapy [14,15]. However, CD8 CTL
lones recognizing recipient minor H antigens can be
solated after transplantation from most patients un-
ergoing allogeneic HCT from an MHC-matched,
elated donor [16], and a subset recognize recipient
ematopoietic cells but not nonhematopoietic cells in
itro, thus suggesting that they may be speciﬁc for he-
atopoietic lineage-speciﬁc genes. It is not possible to
apidly identify the genes encoding the antigens and
omprehensively analyze tissue expression in all pa-
ients who relapse. Thus, the safety of adoptively
ransferring CTLs selected on the basis of recognition
f recipient hematopoietic target cells but not skin
broblasts to patients with acute leukemia who relapse
fter HCT is currently being investigated.
The most frequent toxicities observed with the
nfusion of minor H antigen–speciﬁc CTL clones
ave been fever and chills, which occurred in all pa-
ients, and pulmonary inﬁltrates, which occurred in a
inority of patients. GVHD was considered the most
ikely toxicity of infusing minor H antigen–speciﬁc
TLs but occurred in a minority of patients on this
tudy, and the role of T-cell infusions as a causative
actor could not be deﬁnitively established in any of
he patients. Thus, the strategy of selecting T-cell
lones solely on the basis of in vitro assays will not be
ufﬁcient for ensuring safety in all patients. This illus-
rates the importance of ongoing efforts to molecu-
arly characterize minor H antigens to identify addi-
ional antigens that are selectively expressed in
ematopoietic cells as targets for immunotherapy.
A subset of patients treated with infusions of
inor H antigen–speciﬁc CTLs had persistent leu-
emia after receiving chemotherapy for relapse and
chieved a remission only after the T-cell infusions.
lthough these results provide encouraging evi-
ence that transferred T-cell clones exert antileu-
emic activity, the patients later relapsed. The per-
istence of transferred T cells was measured by
uantitative polymerase chain reaction that used
rimers to amplify clone-speciﬁc sequences of the
-cell receptor  gene. High levels of transferred
ells were detected in the blood and bone marrow
hortly after the cell infusions, but persistence of
ransferred T cells was not optimal. A short dura-
ion of in vivo persistence of transferred T-cell
lones has been observed in other studies [17] and
B&MTay contribute to the lack of sustained treatment
fﬁcacy.
A critical question with implications for efforts
o use adoptive transfer of T-cell clones for cancer
s whether the failure of minor H antigen–speciﬁc T
ells to persist in vivo is due to intrinsic properties
f differentiated effector T-cell clones that are ac-
uired during prolonged ex vivo culture or due to
xtrinsic factors such as activation-induced cell
eath, inadequate CD4 T helper responses, or lack
f prosurvival cytokines [18]. To address these is-
ues and identify improved regimens for cell trans-
er that might be applied in humans, studies have
een initiated in nonhuman primates in which an-
igen-speciﬁc T-cell clones are isolated and propa-
ated under culture conditions identical to those of
uman T-cell clones. The clones are genetically
arked before transfer to facilitate the analysis of
heir persistence and migration in vivo. Preliminary
esults of these studies demonstrate that differenti-
ted effector T cells do retain the capacity to survive
ong-term in vivo. Moreover, the transferred T cells
igrate widely to lymphoid organs and acquire phe-
otypic and functional characteristics of memory T
ells. However, without exogenous cytokines, only a
inor proportion of transferred cells are capable of
ersisting as memory cells when transferred into a
ull lymphoid compartment. Ongoing studies are
ddressing whether cytokines such as interleukin 2
r interleukin 15 or modiﬁcations of the host lym-
hoid environment can promote in vivo expansion
nd persistence of transferred T-cell clones [19,20].
t is anticipated these studies will instruct future
fforts toward adoptive transfer of T-cell clones
argeting leukemic cells after allogeneic HCT.
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